Compare · CBLI vs MEDP
CBLI vs MEDP
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.18B, about 323.5x CBLI ($53.1M).
- MEDP has hit the wire 5 times in the past 4 weeks while CBLI has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- Medpace Holdings Inc.
- Price
- $3.20-9.22%
- $601.25-0.69%
- Market cap
- $53.1M
- $17.18B
- 1M return
- -
- +17.26%
- 1Y return
- -
- +33.21%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2016
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest MEDP
- SEC Form 10-Q filed by Medpace Holdings Inc.
- Medpace Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medpace Holdings, Inc. Reports Second Quarter 2026 Results
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)